About Hevilo Life Sciences' Early Access Program (EAP) Hevilo's EAP is a fee-based non-experimental pre-launch program whereby feedback from qualified subjects is incorporated into final ...

Named Patient Program enables physicians to prescribe the Company's novel Mazindol Extended-Release formulation to patients who have failed approved therapies Product sales through the NPP are ...

MTX-001 is also being studied in an ongoing multicenter, Phase 2 double-blind, placebo-controlled trial focused on venous leg ulcers (VLUs). The company is actively expanding collaborations with ...

Oral presentation will highlight new data in Early Access Program (EAP) for patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013. This is the seventh year that MaaT Pharma's ...

The Savara Early Access Program has been reviewed and allowed to proceed by the U.S. Food and Drug Administration (FDA), and it is currently accepting requests from eligible patients in select ...

The Early Assessment Program (EAP) is a collaborative effort among the State Board of Education (SBE), the California Department of Education (CDE) and the California State University.

Combined with the creation of our Early Access Program, this launch brings us closer to providing global access to highly accurate, affordable prenatal care for all pregnant people," said Dirk van ...

These Early Assurance Programs (EAP) give undergraduate students the opportunity to secure a spot in medical school early as early as their sophomore year.

Named Patient Program (NPP) enables physicians to prescribe the Company's novel Mazindol Extended-Release (ER) formulation to patients who have failed ...

Combined with the creation of our Early Access Program, this launch brings us closer to providing global access to highly accurate, affordable prenatal care for all pregnant people," said Dirk van ...